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GOAL
The purpose of this report is to pay attention to the 
problem of late cardiac complications, which 
develop in remote (distant) period after combined 
therapy (beam and chemotherapy) of Hodgkin’s 
lymphoma on example of illustrative clinical case
 During the past five decades, dramatic progress 
has been made in the development of curative 
therapy for hematologic malignancies, 
including Hodgkin’s Lymphoma
 The therapy responsible for this survival can 
also produce adverse long-term health-related 
outcomes, referred to as late effects, which 
manifest months to years after completion of 
cancer treatment
INTRODUCTION
 Second malignancies (leukemia, lung, stomach, 
breast, bone, colorectal cancers, etc.)
 Cardiac disease
 Pulmonary dysfunction
 Infections
 Endocrinopathy
MOST SUBSTANTIAL LATE 
COMPLICATIONS AFTER TREATMENT 
FOR HODGKIN’S LYMPHOMA
CUMULATIVE INCIDENCE OF 
CAUSE-SPECIFIC MORTALITY
Blood 2014 124:3373-3379; doi: https://doi.org/10.1182/blood-2014-05-579193 
 Coronary artery disease 
 Arrhythmias
 Valvular disease
 Pericardial disease 
CLINICALLY SIGNIFICANT 
CARDIAC EVENTS
BMJ 2009;339:b4606 
CUMULATIVE INCIDENCE OF CARDIAC 
DISORDERS AMONG CHILDHOOD SURVIVORS 
BY ANTHRACYCLINE DOSE
BMJ 2009;339:b4606 
CUMULATIVE INCIDENCE OF CARDIAC 
DISORDERS AMONG CHILDHOOD SURVIVORS 
BY AVERAGE CARDIAC RADIATION DOSE
Bleomycine Induced Pneumofibrosis
• 0-40% patients develop pulmonary toxicity
• 11-30% patients have non-lethal pulmonary 
fibrosis 
• 2-10% mortality 
30% of patients develop nephrotoxicity: 
coagulation necrosis of proximal and distal 
renal tubular epithelial cells and in the 
collecting ducts
Adriamycine Induced Nephrotoxicity
OUR PATIENT
37 Yr Female
COMPLAINTS
 Dyspnea during exertion (especially when going 
uphill or upstairs), ordinary physical activity 
cause breathlessness 
 Edema of ankles in the evening
 Face and eyelid puffiness in the morning
 Palpitations
 Tendency to low blood pressure (85/55 mmHg)
 In 1993 Hodgkin's Lymphoma of mandibular, cervical, 
intrathoracic lymph nodes had been diagnosed
 The combination therapy had been carried out
 Chemotherapy: particular regimens and medicines  patient 
currently  do not remember
 Bilateral cervical, supra-, infraclavicular, axillar as well as 
mediastinal regions radiotherapy had been performed 
 Since 1996 remission occurs, relapses did not observe
HISTORY OF THE PRESENTING COMPLAINTS
HISTORY OF THE PRESENTING COMPLAINTS
 Since 2013 dyspnea and ankle swelling bother the 
patient
 She was surveyed in cardiologic center and for the first 
time was established diagnosis of  
“Mild pericardial effusion. Chronic congestive heart 
failure II FC NYHA”
It was prescribed:
SALT RESTRICTION in diet (< 3 g per day)
TORASEMIDE 5 mg in the morning and  
IVABRADINE 7.5 bid
 Symptoms decreased (but not completely ceased), 
exercise tolerance slightly improved
 During the last month dyspnea and exercise 
intolerance were exacerbated, even ordinary physical 
activity and walking ground level less then 500m led to 
breathlessness
 Also palpitations had developed
 Due to symptoms deterioration, patient had been 
referred to cardiologic department
HISTORY OF THE PRESENTING COMPLAINTS
PAST MEDICAL HISTORY
 In 2001 when she was pregnant heart murmurs 
were discovered
 Mitral valve prolapse 1st degree was diagnosed
 Correction was not required at that moment
DRUG HISTORY
 TORASEMIDE 5 mg qd in the morning 
 IVABRADINE 7.5 bid
ALLERGIES AND REACTIONS
 Patient has not any allergies
 Patient has not any reactions to drugs and 
medication
ALCOHOL AND SMOKING
 Patient does not consume alcohol 
 Patient does not smoke
SOCIAL HISTORY
 Patient is married and has 2 children , first one was 
born in 2001 and second child was born in 2003
 She lives in a separate apartment with her family
 All household chores carries out herself, she does not 
require any social help
 Patient works as an accountant and she is not stressed 
working for this job
EXAMINATION
VITAL SIGNS : 
 Height of the patient – 160 cm 
 Weight of the patient – 52 kg
 Temperature – 36.7oC
 Blood pressure – 80/60 mmHg
 Pulse – 110 bpm
 Respiratory rate – 30 pm 
Hypotension and tachycardia occurs
GENERAL CONDITION
 Well groomed and good mood female
 The general condition of the patient is satisfactory, 
she is not in distress 
 The consciousness is clear, she is well oriented in 
time and surroundings, speaking in full sentences
EXAMINATION
SKIN AND MUCOUS MEMBRANES
 Skin is pale pink and clear, skin turgor and elasticity are 
preserved, on the lower part of the neck to the left present 
small scar due to lymph node biopsy in 1995 
 Subcutaneous fat tissue is well developed 
 Nails’ examination is unremarkable
 Mucous membranes are pink and wet
 Tongue is clear and wet
 Edema is absent at the time of inspection
 All groups of lymph nodes are not palpable, in the axillar
region to the right palpated dense scar tissue (painless, 
possibly post beam therapy)
EXAMINATION
JOINTS, HEAD & NECK
 Joints are without any abnormalities
 The head examination is unremarkable
 The neck has normal shape and size, no visible 
enlargement of thyroid gland 
 Thyroid gland is palpated, size is slightly 
increased, painless, has smooth surface, 
homogeneous structure, nodules are not detected
 JVP 4.7 cm above the sternal angle
EXAMINATION
RESPIRATORY & CARDIOVASCULAR SYSTEMS
 The chest has normal shape and size
 Pulmonary percussion: during  comparative and topographic 
percussion , sound was resonant, lung borders are not changed 
 Lung auscultation: vesicular breath sound, additional sounds 
are not present
 Apex beat localized in the 5th intercostal space, distance from 
midsternum is 8.5 cm in the recumbent posture, diffuse and
diminished force
 Ausculation of the heart: S1 and S2 are soft, systolic murmur 
heard over mitral valve, pericardial friction rub along the left 
sternal border
EXAMINATION
GIT & URINARY SYSTEMS
 Abdomen is soft and nontender, no rebound
 Liver percussion: 13/12/9 cm
 Liver is palpated 4 cm lower than right costal arch, 
nontender and soft, and has smooth surface 
 Spleen percussion: 10/15 cm
 Spleen is palpated 6 cm lower than left costal arch, 
tenderless, and elastic consistency 
 The kidneys are not palpable
 Urine is pale yellow in color , daily diuresis is about  1200 
ml/day
 Stool is dark brown in color, formed
Hepatosplenomegaly
EXAMINATION
INVESTIGATION METHODS
1. Complete blood count
2. General urine test
3. Biochemical blood tests (ALT, AST levels, bilirubin
levels, creatinine, BNP)
4. Thyroid function tests
5. ECG
6. 24 hour monitoring ECG
7. US of heart 
8. Chest X-ray
9. CT scan of chest
10. US abdomen
11. US of thyroid gland  
Complete blood count on the day of admission
ESR 10 mm/h
All results falls under normal range 
WBC (N 4,0-9,0 10*9/L) 5.5 10*9/L
NE (N 1,7-7,7 10*9/L; 47,0-72% ) 2.9 10*9/L 53.1%
LY (N 0,4-4,4 10*9/L; 19,0-37,0%) 2.0 10*9/L 35.6%
MO (N 0,0-0,8 10*9/L; 3,0-11,0%) 0.5 10*9/L 9.2%
E (N 0,0-0,6 10*9/L; 0,5-5,0%) 0.0 10*9/L 0.7%
BA (N 0,0-0,2 10*9/L; 0,0-1,0%) 0.1 10*9/L 1.4%
RBC (N 3,9-5,0 10*12/L) 4.28 10*12/L
Hb (N 120-160 g/L) 119 g/L
PLT (N180-320 10*9/L) 245 10*9/L
CLINICAL DATA
Urine analysis on the date of admission
Urine analysis falls into normal range 
Colour Light yellow
Specific gravity (N 1,001-1,040) 1,015
pH (N 5,0-7,0) 5.0
Protein (N absent) Absent 
Glucose (N absent) Absent
Eritrocytes (N single) 0-1/HPF
Leucocytes (N 6-8 in field) 3-4/HPF
Transitional epithelium (N single) 0-1/HPF
Casts: hyliane, granular, etc. (N single) Absent
Crystals (N absent) Absent
CLINICAL DATA
Biochemical blood profile on the date of admission
Plasma glucose (3.9 - 6.4 venous blood) ̶ 4.4 mmol/L
Liver function tests fall in reference range
Bilirubin Total
(N 17-21 mkmol/L)
5.2
mkmol/L
AST
(N < 31 U/L)
16 U/L
ALT
(N < 31 U/L)
26 U/L
CLINICAL DATA
Biochemical blood profile on the date of admission
• eGFR = The Cockcroft and Gault formula (1973)
CCr={((l 40–age) x weight)/(72xSCr)}x 0.85 (if female)
Units : CCr (creatinine clearance) = mL/minute , Age = years ,Weight = kg , SCr
(serum creatinine) = mg/dL
= 60 ml/min/1.73m2 
Kidney function: there is decrease in GFR, iatrogenic hypokalemia
Creatinine
(N 53-97 mkmol/L)
97
mkmol/L
Serum Na
(N 135-145 mmol/L)
137
mmol/L
Serum K
(N 3.5-5.1 mmol/L)
3.2
mmol/L
CLINICAL DATA
TSH
(N 0.25-5 mkU/mL)
2.60 mkU/mL
Thyroid hormones falls into normal range
Biochemical blood profile on the date of admission
CLINICAL DATA
Biochemical blood profile on the date of admission
All results fall into normal range; ESR, C-RP results 
shows absence of inflammation; rheumatoid factor 
shows normal autoantibodies; ASL-O represents 
absence of streptococcal infection
C-RP
(N < 6 mg/L)
< 6 mg/L
Rheumatoid factor
(N <8 IU/mL)
< 8 IU/mL
ASL-O
(N <200 IU/mL)
< 200 IU/mL
CLINICAL DATA
ECG 
CLINICAL DATA
Sinus rhythm, 88 bpm, electrical alternans, vertical heart axis, complete RBBB, left ventricle overload, PR-
segment depression in II, III, AVF, PR-segment elevation in AVR, ST-segment  depression in I, II, III, AVF, V1-
V6, ST-segment elevation in AVR, V1
I
II
III
AVR
AVL
AVF
V1
V2
V3
V4
V5
V6
ECG
Sinus rhythm, 88 bpm, electrical alternans, vertical heart axis, complete 
RBBB, left ventricle overload, PR-segment depression in II, III, AVF, PR-
segment elevation in AVR, ST-segment  depression in I, II, III, AVF, V1-V6, 
ST-segment elevation in AVR, V1
CLINICAL DATA
I
II
III
AVR
AVL
AVF
V1
V2
V3
V4
V5
V6
24 hour monitoring ECG
1) Sinus rhythm 
2)Mean frequency 73 bpm (daytime 79 bpm, nighttime 
63 bpm)
3) Min frequency 56 bpm
4) Max frequency 120 bpm
5) Single supraventricular premature beats (19 SPB)
6) Single ventricular premature beats (6 SPB)
7) Ischemic changes of ST-T were not observed
Significant abnormalities are not detected
CLINICAL DATA
Echocardiography
 Heart chambers: septal thickness 8 mm, LV posterior wall 
thickness 8 mm
Left ventricle 
EDD 40 mm   EDV 67 ml   Stroke volume 47 ml 
ESD 17 mm     ESV 20 ML
Right ventricle diameter 24 mm
 Aortic valve fibrosis and regurgitation I degree
 Mitral valve prolapse I degree
 Pericardial effusion:
posterior wall 3,5 mm
anterior wall 7 mm
apex 2,5 mm
 Collapse of inferior vena cava on inspiration more then 50%
 Heart contractility is preserved (EF 75%)
Mild pericardial effusion is present, myocardial 
contractility is preserved, aortic fibrosis and 
regurgitation I degree, mitral valve prolapse I degree
CLINICAL DATA
CLINICAL DATA
Echocardiography
Echocardiography
By Comparision
IN 2016: 
Pericardial effusion:
posterior wall 3,5 mm
anterior wall 7 mm
apex 2,5 mm
Ejection fraction is 75%
The amount of fluid in pericardial sac decreased 
insighnificantly
IN 2015: 
Pericardial effusion:
posterior wall 5 mm
anterior wall 8 mm
apex 3 mm
Ejection fraction is 75%
CLINICAL DATA
Chest CT scan
 Signs of fibrosis of the lungs roots, likely beam 
therapy etiology
 Minimal upper mediastinal lymphadenopathy 
(paratracheal region); no reliable progression by 
comparison with 2008 year
 Cardiomegaly, mild hydropericardium (max fluid 
thicness 14 mm); occurrence of hydropericardium by 
comparison with 2008 year
 Diffuse changes in thyroid gland structure
Lung fibrosis and cardiomegaly with mild 
hydropericardium are detected
CLINICAL DATA
U.S of thyroid gland 
 Thyroid gland is enlarged (goiter– 1st degree)
 Diffuse parenchyma changes: in both lobes 
occurs multiple cysts 2.5-4.0mm in diameter and 
hypoechogenic heterogenic inclusions with 
cystic component (right lobe 4.5*7.5mm in 
diameter and left lobe 9.5*7.5mm in diameter)
Goiter ( 1st degree ) with diffuse nodular 
parenchyma changes is seen 
CLINICAL DATA
U.S of Abdomen 
 Liver : right lobe 15,5 cm, left lobe 8 cm; focal lesion 
of the 3rd segment of left lobe 10×12 mm in diameter
 Spleen: 7.5 cm/15 cm
 Left kidney: diminished in size (32×65 mm), lumbar 
displacement, diffuse hyperechogenicity of the 
parenchyma, thinning of the cortex, hypoechogenic
inclusions (at least 2 inclusions) 6-14mm in 
diameter
 Right kidney has normal size (56×103 mm)
 Urolithiasis of both kidneys(2-4mm in diameter)
Hepatosplenomegaly, hemangioma of the left lobe of 
liver is seen; left kidney hypoplasia; urolithiasis
CLINICAL DATA
Cardiac surgeon consultation
Diagnosis:
Chronic effusive pericarditis, not compressive. 
Chronic heart failure I-II FC
At the moment patient does not require surgical 
treatment of pericarditis, but only conservative 
treatment 
CONSULTATION 
CONSULTATION 
Endocrinologist
Diagnosis:
Diffuse goiter I degree, euthyroidism
Condition does not require any correction at the present 
time  
CLINICAL SYNDROMES
 Pericardial effusion
 Heart failure
 Cardiosclerosis
 Pneumofibrosis
 Chronic kidney disease
 Hepatosplenomegaly
 Goiter
Pericardial effusion
2015 ESC Guidelines for the diagnosis and management of pericardial diseases 
Clinical Syndromes Classification
Grading the size of an effusion by 
echocardiography measurements 
 Physiologic/trivial 
echo-free pericardial space < 5 mm ≈ 50-100 ml of fluid
 Small
echo-free pericardial space 6-9 mm ≈ 100-250 ml of fluid
 Moderate
echo-free pericardial space 10-19 mm ≈ 250-500 ml of 
fluid
 Large
echo-free pericardial space >20 mm ≈ >500 ml of fluid
Clinical Syndromes Classification
Pericardial effusion
According to the composition of the fluid
 Serous
 Purulent
 Fibrinous
 Caseous
 Hemorrhagic
Clinical Syndromes Classification
HEART FAILURE
Classification by time course
 Acute heart failure 
 Chronic heart failure 
Anatomical classification
Left sided heart failure 
Right sided heart failure 
Total heart failure (Congestive HF)
Clinical Syndromes Classification
Heart Failure
The New York Heart Association (NYHA) 
Functional Classification
ClassPatient Symptoms
I No limitation of physical activity. Ordinary physical activity
does not cause undue fatigue, palpitation, dyspnea (shortness
of breath).
II Slight limitation of physical activity. Comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnea (shortness of breath).
III Marked limitation of physical activity. Comfortable at rest. Less
than ordinary activity causes fatigue, palpitation, or dyspnea.
IV Anable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is
undertaken, discomfort increases.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Clinical Syndromes Classification
Heart Failure
AHA/ACC Heart Failure Staging
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Class Objective Assessment
A No objective evidence of cardiovascular disease. No symptoms and no
limitation in ordinary physical activity.
B Objective evidence of minimal cardiovascular disease. Mild
symptoms and slight limitation during ordinary activity. Comfortable
at rest.
C Objective evidence of moderately severe cardiovascular disease. 
Marked limitation in activity due to symptoms, even during less-
than-ordinary activity. Comfortable only at rest.
D Objective evidence of severe cardiovascular disease. Severe
limitations. Experiences symptoms even while at rest.
Clinical Syndromes Classification
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Heart Failure
Clinical Syndromes Classification
Cardiosclerosis
 Following myocarditis
 Atherosclerotic 
 Postinfarction
 Focal
 Diffuse
Clinical Syndromes Classification
Interstitial Lung disease
Clinical Syndromes Classification
• Idiopathic disorders
• Connective tissue and autoimmune disease
• Occupational and environmental
• Drug induced
Chemotherapeutic agent
Radiation therapy
Anthyarrhythmics
Antibiotics
Anticonvulsants
• Infections
• Genetic/inherited
Types of Drug Induced Renal Injury in Patients 
with Oncologic Disease
Acute tubular
necrosis,
Interstitial nephritis
Cisplatin, carboplatin, methotrexate, 
mitomycin-C, cyclosporine, 
ifosfamide, zoledronate, 
gemcitabine, interferons, urea 
derivatives, antibiotics, radiopaque
substances
Glomeruli Interferons, VEGF inhibitors, 
adriamycin, mitomycin-C, 
methotrexate, gemcitabine, urea 
derivatives, pamidronate
Renal vascular 
lesions 
VEGF inhibitors, mitomycin-C, 
gemcitabine, cisplatin, bleomycin
Clinical Syndromes Classification
Clinical Syndromes Classification
Chronic Kidney Disease
Causes of Hepatomegaly with Splenomegaly
 Chronic liver disease with portal hypertension: any 
cause of liver disease
 Hematological disease: Myeloproliferative disease, 
Leukemia, Lymphoma, Sickle cell anemia, 
Thalassemia, etc.
 Infections: Acute viral hepatitis, CMV/EBV, Malaria, 
Leishmaniasis, etc.
 Infiltration: Amyloidosis, Sarcoidosis
 Miscellaneous: Drug abuse, Acromegaly, SLE,
Multiple sulfatase deficiency, Osteopetrosis
Clinical Syndromes Classification
WHO goiter classification
Clinical Syndromes Classification
Goiter classification according to thyroid 
function
 Non-toxic goiter 
 Toxic goiter
 Hypothyroid goiter
Clinical Syndromes Classification
Goiter classification according to the thyroid 
structure
 Diffuse
 Nodular
Clinical Syndromes Classification
FINAL DIAGNOSIS
Main disease
Hodgkin's Lymphoma, remission
Complications
Late Hodgkin's lymphoma therapy complications:
Chronic mild pericardial effusion, 
Diffuse cardiosclerosis following aseptic myocarditis,
Aortic valve sclerosis,
Sinus tachycardia, right bundle branch block
Chronic congestive heart failure with preserved EF (75%), 
II FC NYHA, 
Hypoplasia? (Druid induced atrophy?) of the left kidney, 
CKD II stage, 
Hepatomegaly with splenomegaly,
Diffuse nodular non-toxic goiter 
Heart Failure
 Diet: salt restriction, rich in potassium 
 Rate control:          IVABRADINE 7.5 mg bid
 Diuresis control:   TORACEMIDE 5 mg qod
 Hypokalemia: POTASSIUM CHLORIDE 600 mg bid
(under control of serum potassium )
 ACE-inhibitors:      RAMIPRIL  1.25 mg qd
MANAGEMENT
Pericardial Effussion
 NSAIDs
Aspirin 500 mg qd
Gastroprotection
Pantoprazole 40 mg qd
MANAGEMENT
 Despite of therapy, pericardial effusion persist 
by control echocardiography data
posterior echo-free 3 mm
anterior echo-free 6 mm
apex echo-free 3.5 mm
 Symptoms ceased insignificantly, physical 
tolerance slightly increased, but lower 
extremities edema and morning eyelid 
puffiness are observed 
OUTCOME
 Patients who have been treated for Hodgkin's
disease, despite being cured of their malignancy, 
may develop iatrogenic complications that lead to
premature mortality
 A substantial excess risk of mortality may be
attributable to second cancers and cardiac
diseases
 Multitude of patients have been treated with
anthracyclines or chest radiation, both of which
may cause cardiovascular and kidney damage
CONCLUSION
 The frequency of long-term complications in
patients treated for Hodgkin's disease makes
continued follow-up an important part of their
care
 This follow-up should include efforts to prevent
morbidity and mortality by early diagnosis and
attention to risk factors
 Future treatment regimens for Hodgkin's disease
should be designed attempting to minimize these 
complications
CONCLUSION

